Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin

Rhea-AI Summary

Creative Medical Technology Holdings (NASDAQ: CELZ) has successfully generated human insulin-producing Islet Cells derived from induced pluripotent stem cells (iPSC) under its iPSCelz® program. This development is validated by Greenstone Biosciences and utilized in several FDA-cleared clinical programs in the U.S. The creation of these cells marks a significant milestone for the company, potentially accelerating clinical applications and saving years of research and development. CEO Timothy Warbington highlighted the cost-efficiency and regulatory adherence of the company's multiple programs while maintaining a lower burn rate compared to peers.

Positive

• Successful generation of human insulin-producing Islet Cells from iPSC.
• Validated by Greenstone Biosciences.
• Utilized in multiple FDA-cleared clinical programs.
• Potential acceleration in clinical applications and R&D savings.
• Cost-efficient program management with slower burn rate.

Negative

• None.

PHOENIX, June 24, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that it has successfully generated human induced pluripotent stem cells (iPSC)-derived Islet Cells that produce human insulin.

The iPSC clinical line that generated these insulin producing Islet Cells is part of the Company’s iPSCelz^® program, which is validated by Greenstone Biosciences Inc. (“Greenstone”). The iPSC clinical line, which is currently utilized in a number of our FDA cleared clinical programs in the U.S., has also been utilized to derive validated mesenchymal cells and T-regulatory cells.

Timothy Warbington, President and CEO of the Company, commented, “The production of human insulin from islets derived from the IPSCelz^® program is a significant milestone for the Creative Medical Team and a reflection of the leadership role we have assumed in developing these therapies. It was only year ago that we confirmed the development of our iPSC. As we said then, we estimated that the development of this cell line would save the Company two to three years in research and development time along with associated expenses. Today, we are thrilled to be able to announce the evolution of this program with the creation of insulin producing Islet Cells derived from our iPSC. We believe that this development has the potential for not only clinical translation of the human Islet Cells, but also the stand-alone human insulin which is produced by these cells. We are currently in strategic discussions on “next step” collaborations to further these programs.”

“The Company continues to achieve significant milestones with its multiple programs in a cost-efficient manner without sacrificing quality and maintaining strict adherence to all regulatory requirements,” Mr. Warbington continued. “We are focused on allocating our resources in a prudent and effective manner which we believe is evidenced by our achievements and a slower burn rate than many companies in our space.”

About IPSCelz^®
iPSCelz^®, which is protected by trade secrets and published U.S. patents, utilizes the companies xeno-free human perinatal cell line derived from qualified human donors which are then converted into IPS cells. These cells are incubated with the Company’s cell-free reprogramming “cocktail” to create the human islets and other cell types.

About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in stem cell technology in the fields of immunotherapy, urology, neurology, and orthopedics. For further information about the Company, please visit www.creativemedicaltechnology.com. 

Forward Looking Statements
This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.

Company Contact	Investor Relations
Creative Medical Technology	Devin Sullivan, Managing Director
IR@CreativeMedicalTechnology.com	The Equity Group Inc.
	dsullivan@equityny.com
	Conor Rodriguez, Analyst
	crodriguez@equityny.com

FAQ

What did Creative Medical Technology announce about its iPSCelz program?

Creative Medical Technology announced the successful generation of human insulin-producing Islet Cells derived from iPSCs under its iPSCelz program.

When did Creative Medical Technology announce the success in generating insulin-producing Islet Cells?

Creative Medical Technology announced this development on June 24, 2024.

What is the significance of the insulin-producing Islet Cells generation for CELZ?

The generation of insulin-producing Islet Cells marks a key milestone, potentially speeding up clinical applications and saving years of research and development time for CELZ.

How is the iPSCelz program validated?

The iPSCelz program is validated by Greenstone Biosciences.

What are the financial benefits highlighted in the PR for CELZ?

The PR highlights cost-efficient program management, regulatory adherence, and a slower burn rate compared to peers, as financial benefits for CELZ.